US 11,685,750 B2
Crystalline forms of IRAK degraders
Xiaozhang Zheng, Lexington, MA (US); and Don Corson, East Rutherford, NJ (US)
Assigned to Kymera Therapeutics, Inc., Watertown, MA (US)
Filed by Kymera Therapeutics, Inc., Watertown, MA (US)
Filed on Jun. 3, 2021, as Appl. No. 17/338,420.
Claims priority of provisional application 63/034,088, filed on Jun. 3, 2020.
Prior Publication US 2021/0395273 A1, Dec. 23, 2021
Int. Cl. C07D 519/00 (2006.01); A61P 29/00 (2006.01)
CPC C07D 519/00 (2013.01) [C07B 2200/13 (2013.01)] 29 Claims
 
1. A crystalline solid form of compound 1:

OG Complex Work Unit Chemistry
wherein the crystalline solid form is selected from the group consisting of Form A of compound 1 and Form B of compound 1; and wherein:
Form A of compound 1 is characterized by three or more peaks in its X-ray powder diffraction pattern selected from those at about 6.0, about 16.5, about 17.2, about 23.0, and about 23.9 degrees 2-theta; and
Form B of compound 1 is characterized by three or more peaks in its X-ray powder diffraction pattern selected from those at about 3.2, about 16.2, about 16.5, about 17.1, and about 18.2 degrees 2-theta.